Functions and novel regulatory mechanisms of key glycolytic enzymes in pulmonary arterial hypertension
Copyright © 2024 Elsevier B.V. All rights reserved..
Pulmonary arterial hypertension (PAH) is a progressive vascular disease characterized by remodeling of the pulmonary vasculature and elevated pulmonary arterial pressure, ultimately leading to right heart failure and death. Despite its clinical significance, the precise molecular mechanisms driving PAH pathogenesis warrant confirmation. Compelling evidence indicates that during the development of PAH, pulmonary vascular cells exhibit a preference for energy generation through aerobic glycolysis, known as the "Warburg effect", even in well-oxygenated conditions. This metabolic shift results in imbalanced metabolism, increased proliferation, and severe pulmonary vascular remodeling. Exploring the Warburg effect and its interplay with glycolytic enzymes in the context of PAH has yielded current insights into emerging drug candidates targeting enzymes and intermediates involved in glucose metabolism. This sheds light on both opportunities and challenges in the realm of antiglycolytic therapy for PAH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:970 |
|---|---|
| Enthalten in: |
European journal of pharmacology - 970(2024) vom: 05. Apr., Seite 176492 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Jia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiglycolytic agents |
|---|
| Anmerkungen: |
Date Completed 02.04.2024 Date Revised 02.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejphar.2024.176492 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369930053 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369930053 | ||
| 003 | DE-627 | ||
| 005 | 20240403000536.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejphar.2024.176492 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1361.xml |
| 035 | |a (DE-627)NLM369930053 | ||
| 035 | |a (NLM)38503401 | ||
| 035 | |a (PII)S0014-2999(24)00180-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Jia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Functions and novel regulatory mechanisms of key glycolytic enzymes in pulmonary arterial hypertension |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.04.2024 | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a Pulmonary arterial hypertension (PAH) is a progressive vascular disease characterized by remodeling of the pulmonary vasculature and elevated pulmonary arterial pressure, ultimately leading to right heart failure and death. Despite its clinical significance, the precise molecular mechanisms driving PAH pathogenesis warrant confirmation. Compelling evidence indicates that during the development of PAH, pulmonary vascular cells exhibit a preference for energy generation through aerobic glycolysis, known as the "Warburg effect", even in well-oxygenated conditions. This metabolic shift results in imbalanced metabolism, increased proliferation, and severe pulmonary vascular remodeling. Exploring the Warburg effect and its interplay with glycolytic enzymes in the context of PAH has yielded current insights into emerging drug candidates targeting enzymes and intermediates involved in glucose metabolism. This sheds light on both opportunities and challenges in the realm of antiglycolytic therapy for PAH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antiglycolytic agents | |
| 650 | 4 | |a Glycolytic enzymes | |
| 650 | 4 | |a Pulmonary arterial hypertension | |
| 650 | 4 | |a Warburg effect | |
| 700 | 1 | |a Liu, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Shen-Shen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hui-Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Chun-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Jing-Si |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ruo-Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Lian, Tian-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xian-Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Yue-Jiao |e verfasserin |4 aut | |
| 700 | 1 | |a Jing, Zhi-Cheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pharmacology |d 1967 |g 970(2024) vom: 05. Apr., Seite 176492 |w (DE-627)NLM000029769 |x 1879-0712 |7 nnns |
| 773 | 1 | 8 | |g volume:970 |g year:2024 |g day:05 |g month:04 |g pages:176492 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejphar.2024.176492 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 970 |j 2024 |b 05 |c 04 |h 176492 | ||